Title :

Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the platum trial

Author(s) :

Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM]
Devos, Patrick [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Houillier, Caroline [Auteur]
Service d'Onco-neurologie = Département de neurologie 2 [CHU Pitié Salpêtrière]
Cartalat, Stephanie [Auteur]
Service de neuro-oncologie [Hôpital Pierre Wertheimer - HCL]
Chinot, Olivier [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Di Stefano, Anna Luisa [Auteur]
UPMC - Département de neurologie 2 - Mazarin
Lepage, Clement [Auteur]
Reyns, Nicolas [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Dubois, François [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]

Journal title :

Neurology

Publisher :

American Academy of Neurology

Publication date :

2019-10-04

ISSN :

0028-3878

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.METHODS: In the PLATUM phase II open-label, ...
Show more >OBJECTIVE: To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.METHODS: In the PLATUM phase II open-label, multicenter, single-arm trial, patients diagnosed with Common Terminology Criteria for Adverse Events grade 3 or 4 thrombocytopenia during chemoradiotherapy received weekly subcutaneous romiplostim injections. PLATUM aimed at demonstrating that the percentage of thrombocytopenic patients treated with romiplostim able to complete 6 cycles of maintenance temozolomide chemotherapy exceeded 10% (ppRESULTS: Twenty patients were enrolled in step 1. Median age was 61 years (range 33-73). Twelve patients received 6 temozolomide cycles, corresponding to a success rate of 60% (95% confidence interval 36%-81%). Four patients discontinued temozolomide because they did not respond to romiplostim, 2 for progression, and 2 for adverse events unrelated to romiplostim.CONCLUSIONS: The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia.NCT02227576.METHODS: This study provides Class IV evidence that for patients with glioblastoma and thrombocytopenia, romiplostim is effective for the secondary prophylaxis of temozolomide-induced thrombocytopenia.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Collections :

• Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189

Source :

Harvested from HAL